These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 17317846)

  • 21. Ras/MEK pathway is required for NGF-induced expression of tyrosine hydroxylase gene.
    Suzuki T; Kurahashi H; Ichinose H
    Biochem Biophys Res Commun; 2004 Mar; 315(2):389-96. PubMed ID: 14766220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.
    Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT
    Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells.
    Ingeson-Carlsson C; Nilsson M
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):241-54. PubMed ID: 23969277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
    Takahashi K; Eguchi H; Arihiro K; Ito R; Koyama K; Soda M; Cologne J; Hayashi Y; Nakata Y; Nakachi K; Hamatani K
    Mol Carcinog; 2007 Mar; 46(3):242-8. PubMed ID: 17186541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
    Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
    Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
    J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
    Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis.
    Jiang CC; Chen LH; Gillespie S; Wang YF; Kiejda KA; Zhang XD; Hersey P
    Cancer Res; 2007 Oct; 67(20):9750-61. PubMed ID: 17942905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
    Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
    Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
    Liu D; Liu Z; Condouris S; Xing M
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2264-71. PubMed ID: 17374713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
    Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [BRAF gene mutation in thyroid cancer].
    Kopczyńska E; Junik R; Tyrakowski T
    Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.
    Oler G; Camacho CP; Hojaij FC; Michaluart P; Riggins GJ; Cerutti JM
    Clin Cancer Res; 2008 Aug; 14(15):4735-42. PubMed ID: 18676742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
    Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.